JP Morgan analyst Rajat Gupta upgrades TrueCar (NASDAQ:TRUE) from Underweight to Overweight.
Amgen Provides Regulatory Update On Status Of Lumakras; FDA Has Issued New Postmarketing Requirement; LUMAKRAS Dosing Confirmed At 960 mg Once-Daily For Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval
FDA Has Issued New Postmarketing Requirement
LUMAKRAS Dosing Confirmed at 960 mg Once-Daily for Patients With KRAS G12C-Mutated NSCLC Under Accelerated Approval
THOUSAND OAKS, Calif., Dec. 26,
